Cargando…

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy

Gastric adenocarcinoma (GAC) is the third most common cause of cancer-related deaths worldwide. Combination chemotherapy remains the standard treatment for advanced GAC. Liposomal irinotecan (nal-IRI) has improved pharmacokinetics (PK) and drug biodistribution compared with irinotecan (IRI, CPT-11)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Awasthi, Niranjan, Schwarz, Margaret A., Zhang, Changhua, Klinz, Stephan G., Meyer-Losic, Florence, Beaufils, Benjamin, Thiagalingam, Arunthathi, Schwarz, Roderich E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Small Molecule Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377761/ https://www.ncbi.nlm.nih.gov/pubmed/35500018 http://dx.doi.org/10.1158/1535-7163.MCT-21-0860

Ejemplares similares

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
por: Barbier, Sandrine, et al.
Publicado: (2023)

Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma
por: Mender, Ilgen, et al.
Publicado: (2023)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models
por: Jiang, Yanyan, et al.
Publicado: (2021)

PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
por: Wu, Cheng, et al.
Publicado: (2021)

Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway
por: Zhang, Wei, et al.
Publicado: (2021)

T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer
por: Li, Dandan, et al.
Publicado: (2021)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models
por: Sun, Danlin, et al.
Publicado: (2021)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development
por: Gill, Sonja J., et al.
Publicado: (2021)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
por: Mirzapoiazova, Tamara, et al.
Publicado: (2021)

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
por: Shagisultanova, Elena, et al.
Publicado: (2022)

Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways
por: Scotto, Luigi, et al.
Publicado: (2021)

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
por: Wang, Yifei, et al.
Publicado: (2022)

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
por: Jernigan, Finith, et al.
Publicado: (2021)

Characterization of Novel α-Mangostin and Paeonol Derivatives With Cancer-Selective Cytotoxicity
por: Nunna, Suneetha, et al.
Publicado: (2022)

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
por: Jo, Ukhyun, et al.
Publicado: (2021)

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2022)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses
por: Stratenwerth, Björn, et al.
Publicado: (2021)

M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models
por: Sanderson, Michael P., et al.
Publicado: (2021)

Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs
por: LeBlanc, Amy K., et al.
Publicado: (2022)

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
por: Zhan, Yue, et al.
Publicado: (2022)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
por: Rice, William G., et al.
Publicado: (2022)

Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
por: Gilbert, Sophie, et al.
Publicado: (2022)

Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
por: Spiliopoulou, Pavlina, et al.
Publicado: (2022)

PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index
por: Casazza, Andrea, et al.
Publicado: (2022)

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
por: Ertveldt, Thomas, et al.
Publicado: (2022)

Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
por: Furman, Craig, et al.
Publicado: (2022)

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
por: Piovesan, Dana, et al.
Publicado: (2022)

Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
por: Scherrer, Didier, et al.
Publicado: (2022)

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
por: Tran, Khanh B., et al.
Publicado: (2022)

Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death
por: Jenkins, Laura J., et al.
Publicado: (2023)

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
por: Jonchere, Barbara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7tjtrknufq24jij6rnpb8pm3mn